Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)
Brief Summary: The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.


Options:
A: Arm Label: Strategy A (Glucose-Dependent); Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Pioglitazone, Drug: Acarbose, Drug: Linagliptin, Drug: Sitagliptin, Drug: Liraglutide, Drug: Exenatide once weekly (QW), Drug: Exenatide twice daily (BID) | Arm Label: Strategy B (Reference); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin, Drug: Pioglitazone, Drug: Acarbose, Drug: Linagliptin, Drug: Sitagliptin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Strategy B (Reference) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Acarbose; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Strategy A (Glucose-Dependent) | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Strategy B (Reference) | Intervention Type: DRUG; Name: Exenatide once weekly (QW); Assigned to Arm(s): Strategy A (Glucose-Dependent) | Intervention Type: DRUG; Name: Exenatide twice daily (BID); Assigned to Arm(s): Strategy A (Glucose-Dependent)
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Placebo/Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin
C: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
D: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin

Answer: A